Pfizer released the following statement in reaction to today’s divided ruling by the U.S. Court of Appeals for the Second Circuit, remanding two cases...brought by Nigerian residents in the U.S. District Court for the Southern District of New York. Plaintiffs are seeking damages under international law in connection with the company’s 1996 Trovan clinical study. "The Appeals Court’s divided decision is only a procedural ruling that may return the cases to the District Court for further consideration; it is not a determination on their merits.... Pfizer remains confident that it will prevail in these cases... “The 1996 Trovan clinical study in Kano was conducted with the approval of the Nigerian government, and consent of the participants’ parents or guardians, and was consistent with both international and Nigerian laws..."